KB Home has just absorbed a cluster of post-earnings analyst revisions, and the gap between where the Street is moving and where short sellers are sitting tells the real story this week.
The analyst reaction to the Q2 print was broadly constructive, but carefully so. Five firms updated targets on June 24, all moving higher — UBS raised to $66 while maintaining Buy, Truist lifted to $56 from $50 while keeping Hold, and Wells Fargo nudged to $52 from $50 but held its Underweight rating. RBC held at $53 with a neutral Sector Perform. The mean target now runs near $57.45, just above the current price of $52.73 — implying limited implied upside and a Street that has re-rated the stock modestly but is far from uniformly bullish. The bull case rests on the company's shift back to its build-to-order model, which carries meaningfully higher margins than its historical mix, and a 3% upward revision to FY26 EPS. The bear case is harder to dismiss: revenues were revised sharply lower before this print, with FY26 EPS still running some 33% below prior consensus estimates according to Benzinga's note from earlier in the year. Goldman Sachs remains Neutral, trimming its target to $56 in March. The stock's P/E of 14.5x and EV/EBITDA near 11x have drifted up over the past month as the price recovered 8.5%, leaving valuation less obviously cheap. The ORTEX factor score on 30-day EPS momentum is a healthy 76, but the 90-day reading ranks at just 9 — a reminder that recent estimate stabilisation follows months of brutal cuts.
Short sellers have not taken the post-print analyst upgrades as a cue to reduce. Short interest is essentially flat on the week at 11.3% of the free float — a genuinely elevated position for a homebuilder — and is fractionally higher on a 30-day basis. Days to cover from FINRA data stands at 7.35, meaning an orderly unwind would take the better part of two weeks. The borrow market is not putting any pressure on that position. Availability is running around 424% of outstanding short interest, meaning roughly four shares are available to lend for every one borrowed — loose by any standard. Cost to borrow has actually eased this week, falling about 15% to 0.44%. The ORTEX short score ticked up to 61.4 from 59.7 at the start of the week, a modest nudge higher but still firmly in the middle of its 10-day range of 59 to 62. The position looks persistent rather than building — shorts are holding, not adding.
Options positioning has normalised after last week's Q2 divergence. The put/call ratio is 0.76, just above its 20-day average of 0.74 — roughly in line with recent history and well below its 52-week high of 1.44. The z-score of 0.59 points to no unusual directional skew in either direction. After the cautious options setup heading into the print last week, derivatives traders have settled into a more balanced stance now that the number is out.
Peers have had a better week than KBH. MTH, PHM, and GRBK are each up 3–4% on the week. LEN is down roughly 2.7%, broadly tracking KBH's 2% weekly decline. The relative underperformance against most of the peer group is notable: KBH printed and got a cluster of analyst upgrades, yet the stock has lagged MTH and PHM by 5-6 percentage points over the same five days. That divergence suggests the post-print analyst enthusiasm has not yet translated into meaningful buying pressure.
The next test is the September 23 earnings event. Between now and then, the debate will be less about whether the Q2 print was good enough and more about whether the build-to-order margin story actually materialises in Q3 deliveries — and whether short sellers, who have now held through a 19% rally and a live print without flinching, see a reason to change their minds.
See the live data behind this article on ORTEX.
Open KBH on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
